<DOC>
	<DOCNO>NCT00531804</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , pharmacokinetics pharmacodynamics R1450 patient mild moderate Alzheimer Disease . Patients randomize receive either R1450 placebo intravenous infusion total 7 dos . The start dose escalate subsequent cohort patient adaptive manner , satisfactory assessment safety , tolerability pharmacokinetics previous dose . The anticipated time study treatment 3-12 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Multiple Ascending Dose Study R1450 Patients With Alzheimer Disease .</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>adult patient , 5090 year age ; diagnosis probable Alzheimer Disease , symptoms &gt; =1 year prior screening ; meet DSMIV criterion Alzheimertype dementia ; stabilise approve medication treatment Alzheimer Disease &gt; =4 month prior baseline . active major depressive disorder , history bipolar disorder ; history schizophrenia ; concurrent participation nonpharmacological trial key objective improve cognition ; prior randomisation R1450 trial .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>